Пређи на садржај

Ksaliproden

С Википедије, слободне енциклопедије
Ksaliproden
IUPAC ime
1-[2-(2-naftil)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridin
Identifikatori
CAS broj135354-02-8 ДаY
ATC kodN07XX03 (WHO)
PubChemCID 128919
ChemSpider114237
UNIIV8QL94KNQO ДаY
KEGGD06327 ДаY
Hemijski podaci
FormulaC24H22F3N
Molarna masa381,433 g/mol
  • FC(F)(F)c4cccc(/C3=C/CN(CCc2cc1ccccc1cc2)CC3)c4
  • InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2 ДаY
  • Key:WJJYZXPHLSLMGE-UHFFFAOYSA-N ДаY

Ksaliproden (SR57746) je lek koji deluje kao 5HT1A agonist.[1] On ima neurotrofno i neuroprotektivno dejstvo in vitro,[2][3] i predložen je kao potencijalni tretman za nekoliko neurodegenerativnih oboljenja, među kojima su amiotrofična lateralna skleroza (ALS)[4] i Alchajmerova bolest.[5]

  1. ^ Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). „MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”. International journal of immunopathology and pharmacology. 18 (1): 21—31. PMID 15698508. 
  2. ^ Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). „Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139—44. PMC 1566010Слободан приступ. PMID 10369466. doi:10.1038/sj.bjp.0702545. 
  3. ^ Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). „Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385—92. PMC 1571767Слободан приступ. PMID 10602316. doi:10.1038/sj.bjp.0702910. 
  4. ^ Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). „Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 5 (2): 107—17. PMID 15204012. doi:10.1080/14660820410019602. 
  5. ^ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). „Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol. 37 (6): 321—7. PMID 12021588. doi:10.1097/00004424-200206000-00003. 

Spoljašnje veze

[уреди | уреди извор]